On Monday, Shares of L Brands Inc (NYSE:LB), gained 0.52% to $83.61.
L Brands, Inc. (LB) stated net sales raised 3% to $1.207 billion for the five weeks ended July 4, 2015, contrast to net sales of $1.176 billion for the five weeks ended July 5, 2014. Comparable store sales for the five weeks ended July 4, 2015, raised 3%.
The company stated net sales of $4.518 billion for the 22 weeks ended July 4, 2015, an enhance of 4% contrast to sales of $4.331 billion for the 22 weeks ended July 5, 2014. Comparable store sales for the 22 weeks ended July 4, 2015, raised 4%.
L Brands, Inc. operates as a specialty retailer of women’s intimate and other apparel, beauty and personal care products, and accessories. The company operates in three segments: Victoria’s Secret, Bath & Body Works, and Victoria’s Secret and Bath & Body Works International.
Shares of Garmin Ltd. (NASDAQ:GRMN), declined -0.89% to $42.51, during its last trading session.
Garmin International, declared an all-digital series of Bluetooth enabled audio panels, the GMA 350c, GMA 35c and GMA 350Hc. Designed for fixed-wing aircraft and helicopters, the GMA 350c series incorporates Bluetooth technology for wireless access to music, phone, Garmin Pilot™ alerts and more. This adds to an impressive list of features, counting industry-first Telligence Voice Command technology and 3D Audio processing, in addition to improved auto squelch capability and more. These features decrease heads-down time and enhance overall situational awareness in the cockpit.
“Garmin continues to focus on simplifying the flying experience with the GMA 350c all-digital Bluetooth audio panel, so pilots can focus more readily on the task at hand – flying the aircraft,” said Carl Wolf, Garmin’s vice president of aviation sales and marketing. “With the GMA 350c, it’s easier to complete important tasks such as opening a flight plan on the ground before departing an uncontrolled field. This, coupled with Telligence Voice Command and 3D audio, combine to make this the most-capable audio panel on the market.”
Garmin Ltd., together with its auxiliaries, designs, develops, manufactures, and markets hand-held, wrist-based, and portable and fixed-mount global positioning system (GPS) enabled products; and other navigation, communication, and information products worldwide.
At the end of Monday’s trade, Shares of Vulcan Materials Company (NYSE:VMC), gained 2.57% to $94.03.
Vulcan Materials Company, declared a quarterly cash dividend of ten cents per share on its common stock. The dividend will be payable on September 10, 2015, to shareholders of record at the close of business on August 25, 2015.
Vulcan Materials Company, a member of the S&P 500 index, is the nation’s largest producer of construction aggregates and a major producer of other construction materials.
Vulcan Materials Company produces and sells construction aggregates, asphalt mix, and ready-mixed concrete primarily in the United States. It operates through four segments: Aggregates, Asphalt Mix, Concrete, and Calcium. The Aggregates segment offers crushed stone, sand and gravel, sand, and other aggregates, in addition to related products and services.
Finally, Nektar Therapeutics (NASDAQ:NKTR), ended its last trade with -0.24% loss, and closed at $12.45.
Nektar Therapeutics, stated that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta’s investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], a leading treatment for hemophilia A with more than 11 years of real-world patient experience.
Following on initial presentations of the data in 2014, the publication provides a comprehensive overview of the clinical trial results of BAX 855, which will be marketed in the United States under the brand name ADYNOVATE [Antihemophilic Factor (Recombinant), Pegylated] upon approval. The trial assessed the treatment’s safety and efficacy profiles for bleed prevention with a twice-weekly dosing plan, showing a mean half-life extension of 1.4- to 1.5-fold contrast with ADVATE. The positive study results were originally stated in August of 2014 and supported the company’s December 2014 submission for approval of BAX 855 to the United States Food and Drug Administration (FDA).
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.